Introduction
Prostate cancer (PC) is the most frequently diagnosed male malignancy in the developed world. 1 PC evolves from high grade prostatic intra-epithelial neoplasia lesions which may progress to metastasis diseases. 2 Primary PCs are managed by a variety of treatment options including active surveillance, surgery, and radiation; treatment choices consider multiple factors such as disease severity, patient age and preference. The severity of PCs is graded using the Gleason score (GS) and GS-based World Health Organization (WHO) PC grading system (WHO grade group 1-5) or its equivalent ISUP (the International Society of Urological Pathology) grade. [3] [4] [5] Aproximately 30% of tumors will relapse following surgery, evident by an increase in serum prostate-specific antigen (PSA), a process that is known as biochemical recurrence (BCR). 6 The recurrence is a major progression of PC, which often results in poor prognosis; a large percentage of relapsed PCs will progress to metastatic disease. 7 With a few exceptions, metastases remain incurable. Metastatic PCs are managed with androgen-deprivation therapy, which was based on the seminal discovery of PC proliferation relying on androgen signaling in the 1940s. 8, 9 Nonetheless, metastatic castration-resistant PC (mCRPC) inevitably occurs. 10, 11 Although mCRPC can be treated with taxane-based chemotherapy, androgen receptor (AR)-targeting therapy involving either abiraterone or enzalutamide, [11] [12] [13] and immunotherapy, 14, 15 these treatments offer modest benefits in these patients. 11, 16 The progression of PC is regulated by complex networks, of which our understanding remains limited.
PC tumorigenesis and progression are promoted by the growth factor phosphoinositide 3-kinase (PI3K) pathway, androgen receptor signaling, cell cycle regulators, Myc, and others. 17, 18 Myc is amplified in PC, 19 which initiates the PC process in mice 17 and is associated with PC recurrence and poor prognosis in patients. [20] [21] [22] Myc is well known to collaborate with Ras during tumorigenesis [23] [24] [25] ; this collaboration induces hyperplasia in the prostate. 26 The newly identified PC factor, FAM84B, displays potential connections with both Myc and Ras. The FAM84B and Myc genes are at the chromosomal locus 8q24.21 bordering the centromeric and telomeric end of a 1.2 Mb gene desert region respectively. [27] [28] [29] [30] [31] Amplification of 8q24 occurs most frequently in human cancers, including ovarian, 32 colorectal, 30, [33] [34] [35] breast, 28, [36] [37] [38] [39] prostate, 27, 29, 31, [40] [41] [42] and others. This structural setting suggests a connection between Myc and FAM84B; however, while the oncogenic involvement of Myc has been extensively investigated, the same can hardly be claimed for FAM84B. FAM84B elevation was recently shown to be associated with poor prognosis in esophageal squamous cell carcinoma, 43, 44 and with PC progression. 45 Ras is a potent oncogene regulated by an array of factors. The H-Ras-like suppressor (HRASLS) family consists of five members (HRASLS1-5) in humans, which all possess tumor suppression activities and can repress H-Ras-initiated oncogenic events in vitro. 46 The family has a typical LRAT (lecithin:retinal acyltransferase) homologous domain. 46 We observed that FAM84B contains a LRAT domain and a subregion within this domain that shares a high level of homology to HRASLS1-5. While overexpression of FAM84B elevated DU145 cell invasion and growth in soft agar in vitro, removal of this subregion abolished these activities. Additionally, FAM84B overexpression promoted the growth of xenografts produced by DU145 cells. The enhancement is associated with alterations of a network consisting of 4976 differentially expressed genes (DEGs), which contribute to the enrichment of 51 pathways regulating the Golgi-endoplasmic reticulum (ER) process, cell cycle checkpoints, protein translation and mitochondrial events. Furthermore, these DEGs contain a multigene signature that robustly predicts PC recurrence in two large independent cohorts. Collectively, we provide evidence for FAM84B stimulating PC tumorigenesis likely through a network change.
Methods
Cell culture, plasmids, and stable line construction DU145 cells were purchased from American Type Culture Collection (ATCC), and cultured in Minimum Essential Media (MEM) supplemented with 5% fetal bovine serum (FBS) (Sigma Aldrich, Oakville, ON, Canada) and 1% penicillin-streptomycin (Thermo Fisher Scientific, Burlington, ON, Canada). The cell line was authenticated (Cell Line Authentication Service, ATCC), and routinely tested for Mycoplasma contamination using a polymerase chain reaction (PCR) kit (Abm, Cat#: G238, Toronto, ON, Canada). The FAM84B mutant with deletion of the HRASLS domain was constructed using PCR. Briefly, the fragments N-terminal and C-terminal to the deletions region were amplified using PCR and then ligated together into a retroviral vector. DU145 empty vector (EV/pBabe), FAM84B, or the FAM84B mutant stable lines were constructed using retrovirus as previously described. 47 Briefly, a gag-pol, an envelope (VSV-G; Stratagene), and a designed retroviral vector (EV, FAM84B, or its mutant) were transiently co-transfected into 293T cells at the ratio 1:1:1. At 48 hours post transfection, the virus-containing medium was filtered (0.45-µM filter) and centrifuged (50,000g) for 90 min. The retrovirus pellets were resuspended into medium supplemented with 10 µg/ml of polybrene (Sigma Aldrich, Oakville, ON, Canada). DU145 cells were subsequently infected and selected with puromycin; Stable lines (without selection for single-cell clones) were used as pool populations in this research.
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Invasion assay
Transwell was used for invasion assay. Insert chambers with either a control membrane or a Matrigel membrane (8-µM pore size) for 24-well plates were purchased (Life Sciences Corning ® BioCoat™, USA). Assay was carried out according to the manufacturer's instructions. Cells (10 4 ) were seeded into the top chamber with serumfree medium; medium containing 5% FBS was added to the bottom chambers. Cells going through the membrane were stained with crystal violet (0.5%) and counted.
Soft agar assay
Six-well tissue culture plates were first coated with a bottom layer agar, 2 ml of 0.6% agar dissolved in complete tissue culture medium. Cells (10 4 ) in 2 ml of 0.35% agar dissolved in complete cell culture medium were then seeded on the solidified bottom layer. Cells were cultured for approximately 3 weeks in a tissue culture incubator with moisture by adding 100 μl of complete medium weekly.
Colony formation assay and proliferation assay
Growth curves were constructed by seeding cells into six-well tissue culture plates (10 5 per well), followed by counting cells daily. Colony formation assays were performed by seeding cells in sixwell plates at the designed density; colonies were stained with crystal violet (0.5%) after culture for 2 weeks. Colony numbers were counted and analyzed.
Immunofluorescence staining
Immunofluorescence (IF) staining was performed by fixing cells with paraformaldehyde for 20 min, followed by permeabilization with 0.3% Triton X-100 for 15 min. Cells were then blocked with a blocking buffer (3% donkey serum + 3% bovine serum albumin (BSA) + 0.3% Triton X-100 in PBS) prior to the addition of primary antibodies polyclonal anti-FLAG (a commonly used polypeptide epitope tag) (1:100, Sigma) and monoclonal anti-HA (a tag epitope derived from hemagglutinin) (12CA5, 1:10 of hybridoma conditional medium) at 4°C overnight. 
Immunoprecipitation (IP)
IP was carried out by incubating cell lysates containing 1 mg of protein with individual antibodies and Protein G agarose (Invitrogen) overnight at 4 o C, followed by eight washes with a buffer [50 mM Tris (pH 7.5), 100 mM NaCl, 7.5 mM ethylene glycol-bis(β-aminoethyl ether)-N,N,N′,N′-tetraacetic acid [EGTA], and 0.1% Triton X-100]. Antibodies used for IP were monoclonal anti-HA (12CA5, 1:10 of hybridoma conditional medium) and anti-M2 (1 μg, Sigma). Antibodies used for the western blot were polyclonal anti-FLAG (1:500, Sigma) and polyclonal anti-HA (1:500, Santa Cruz).
Formation of xenograft tumors and lung metastases
Xenografts were generated as previously described. [47] [48] [49] [50] Briefly, DU145 EV or DU145 FAM84B cells (3 × 10 6 ) in 0.1 ml culture media were mixed with Matrigel mixture (BD) at 1:1 (volume : volume), and implanted (one graft/ mouse) subcutaneously (s.c.) into the flank of NOD/SCID mice (6-week-old males, n = 5 per group; The Jackson Laboratory). Tumor growth was monitored through observation and palpation; tumor size was measured every 5 days using calipers. Tumor volume was calculated as V = L × W 2 × 0.52. Animals were sacrificed when tumors reached a volume ⩾1000 mm 3 . Lung metastases were produced via tail vein injection of DU145 EV or DU145 FAM84B cells (10 6 ) into NOD/SCID mice. Endpoints were defined by a weight loss ⩾10%. All animal experiments were performed according to the protocols approved by the McMaster University Animal Research Ethics Board (AUP#: 16-06-24) .
Western blot analysis
Cell lysates were prepared in a lysate buffer [20 mM Tris (pH 7.4), 150 mM NaCl, 1 mM ethylenediaminetetraacetic acid (EDTA), 1 mM EGTA, 1% Triton X-100, 25 Quantification of FAM84B mRNA expression using real-time PCR Total RNA was isolated from either cells or xenograft tissues with the Isol-RNA Lysis Reagent (5 PRIME); reverse transcription was performed using Superscript III (Thermo Fisher Scientific). Quantitative realtime PCR was performed using the ABI 7500 Fast Real-Time PCR System (Applied Biosystems) using SYBR-green (Thermo Fisher Scientific) with the following primers: FAM84B forward 5'-GACCCAC CTAAGTTACAAGGAAG-3', and reverse 5'-GTA GAACACGGAGCATTCCAC-3'; β-Actin forward 5'-TGAAGGTGACAGCAGTCGGT-3', and reverse 5'-TAGAGAGAAGTGGGGTGGCT-3'. Data analysis was performed using the formula: 2 -ΔΔCt . RNA sequencing analysis RNA sequencing analysis was carried out following our established conditions. 51 RNA was extracted from s.c. xenografts using a miRNeasy Mini Kit (Qiagen, No. 217004) according to the manufacturer's instructions; libraries were prepared with TruSeq Ribo Profile Mammalian Kit (Illumina, RPHMR12126) following manufacturer's instructions, and sequenced by BGI (a genomic sequencing center in Shenzhen, China) using the HiSeq 4000 system. RNA sequences were quantified by BGI (www.genomics.cn/ en/navigation/show_navigation?nid=2657) and expressed as fragments per kilobase of exon per million fragments mapped (FPKM) according to the formula: FPKM = 10 6 C/(NL/10 3 ) with C being the number of fragments aligned to a specific gene, N representing the total number of fragments aligned, and L for the combined exon length of a gene. The mapping rates to human reference genome were 77% and 78% for two EV s.c. xenografts as well as 74% and 75% for two FAM84B s.c. xenografts; the analyses of DEGs were focused on human transcripts. DEGs in xenografts (n = 2) produced by DU145 FAM84B cells versus tumors (n = 2) generated from DU145 EV cells were determined using the Poisson distribution method by BGI.
Immunohistochemistry (IHC)

Pathway enrichment analysis
Pathway enrichment analyses for FAM84B-associated DEGs were performed using the Reactome 52 packages in R Software.
Cutoff point estimation
Cutoff point of DEG expression to separate PC recurrence was estimated using Maximally Selected Rank Statistics (the Maxstat package) in R.
Establishing of a multigene panel predicting PC recurrence
The largest TCGA (The Cancer Genome Atlas) provisional dataset within the cBioPortal database 53 were profiled for mRNA expression using RNA sequencing. The dataset was used to select a gene signature predicting PC recurrence among 4976 DEGs using elastic-net logistic regression within the glmnet package in R with the mixing parameter α set at 0.2, 0.5, and 0.8 and cross validation set at 10-fold.
Statistical analysis
Kaplan-Meier survival curves and a log-rank test were performed using the R survival package, and tools provided by cBioPortal. Univariate and multivariate Cox regression analyses were carried out with the R survival package. Timedependent receiver operating characteristic (tROC) analysis was used (the R timeROC package). A two-tailed Student's t test, twoway analysis of variance (ANOVA), and Benjamini-Hochberg post hoc test were performed. A value of p < 0.05 was considered statistically significant.
Results
FAM84B Overexpression promotes DU145 cell invasion and growth in soft agar
We recently showed an upregulation of FAM84B in DU145-derived PC stem-like cells and an association of FAM84B upregulation with PC progression. 45 To investigate whether FAM84B is functionally important in prostate tumorigenesis, we stably expressed an EV or FAM84B in DU145 cells [ Figure 1 (a)]; the respective pool populations of the EV and FAM84B stable lines were used. The overexpression was justified as the basal level of FAM84B expression was substantially lower in nonstem-like or monolayer DU145 cells in comparison with PC3 and LNCaP cells. 45 Based on three independent western blot analyses with α-tubulin as the loading control, FAM84B expression was 25-fold higher in DU145 FAM84B cells compared with DU145 EV cells (p < 0.001 by a two-tailed Student's t HRASLS, H-Ras-like suppressor; NCEHFV, amino acid residues of asparagine (N), cysteine (C), glutamic acid (E), histidine (H), phenylalanine(F), and valine (V).
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Cruz) that we have previously shown to be effective (data not shown); this lack of success might be in part attributable to the low level of endogenous FAM84B expression in DU145 cells. 45 
Characterization of FAM84B-derived oncogenic activities
With our unsuccessful attempt to knockdown FAM84B in DU145 cells, an alternative method was used to further examine the FAM84B-promoted processes of invasion and growth in soft agar in vitro. We first performed a structural analysis and observed similarities between FAM84B and the HRASLS family ( Figure 2 ); a multiple alignment revealed a region in FAM84B marked with residues 119-212 that is conserved with a region in the members of HRASLS ( Figure 2 ). Humans have five HRASLS members (HRASLS1-5), which all display activities suppressing H-Ras in vitro. 46 HRASLS1-5 are enzymes with phospholipase A 1/2 activities and O-acyltransferase activities. 46 The active site is formed by histidine 23 (H23), H35, and cysteine 113 (C113) numbered in HRASLS2 with C113 being the catalytic residue ( Figure 2 ). 46, 55 The catalytic triad is conserved among the five HRASLS except the H35 being functionally replaced by asparagine (N) in HRASLS1 ( Figure 2 ). 46 In FAM84B, both H23 and H35 are conserved but not the catalytic residue C113 ( Figure 2 ). As C113 is required for the enzymatic activities, 46 FAM84B is unlikely to possess either phospholipase A 1/2 activities or O-acyltransferase enzymatic activities.
We further noticed that the conserved FAM84B region (residues 119-212) is actually the LRAT homologous domain [ Figure 3 (a)]. The LRAT 
Evidence suggests an intramolecular interaction between FAM84B molecules
We have attempted to examine whether an intramolecular interaction exists for FAM84B, which may suggest a potential mechanism for FAM84B's actions in PC. For this purpose, we have taken advantage of the FAM84B (ΔHRASLS) mutant and FAM84B tagged with an HA and FLAG epitope, respectively. When both were transiently expressed in 293T cells, immunoprecipitation of one led to co-precipitation of another [ Figure 5 (a)]. When DU145 cells were transiently co-transfected with both, the mutant and wild type FAM84B can be expressed in the cytosol and nucleus; a co-localization can be clearly demonstrated [ Figure  5 (b)]. However, the expression patterns of FAM84B and FAM84B(ΔHRASLS) are not identical [ Figure 5 (b)], suggesting that the observed co-localization was unlikely due to overexpression. Collectively, evidence supports an intramolecular interaction between the FAM84B molecules and the interaction is likely independent of the HRASLS motif.
FAM84B upregulation enhances xenograft tumor formation in vivo
The observed enhancement of DU145 cell invasion and growth in soft agar indicates that FAM84B promotes prostate tumorigenesis. To examine this possibility, we subcutaneously implanted DU145 EV cells and DU145 FAM84B cells in NOD/ SCID mice (n = 5 per group). As expected, a high level of FAM84B expression was shown in xenografts produced by DU145 FAM84B cells at both the protein and mRNA levels [ Figure 6 (a, b); Figure S3 ]. DU145 FAM84B cell-generated 
FAM84B upregulation facilitates PC metastasis
To examine a potential role of FAM84B in facilitating PC metastasis, we injected DU145 EV or DU145 FAM84B cells via the tail vein into NOD/ SCID mice (n = 6 and n = 10 for the former and latter group respectively). The kinetics for animals reaching the endpoint of weight drop ⩾10% was analyzed. In comparison with mice injected with DU145 EV cells, animals receiving DU145 FAM84B cells reached the endpoint more rapidly [ Figure 7 (a)]. As expected, all animals showed lung metastasis ( Figure S4 ). As well, tumors derived from DU145 FAM84B cells expressed a higher level of FAM84B compared with tumors produced by DU145 EV cells [ Figure 7 (b, c)].
AKT (protein kinase B) activation plays an important role in PC metastasis. 56 Consistent with this knowledge, we were able to show an elevation of AKT activation in DU145 FAM84B cell-produced lung metastases compared with DU145 EV cell-derived metastases [ Figure 8 (a)].
One of AKT's most well-studied functions is its pro-survival role, 57 suggesting a survival advantage in lung metastases produced by DU145 FAM84B cells. To further investigate this possibility, we examined the pro-apoptotic protein BAD in the above lung metastases and observed a significant reduction of BAD in DU145 FAM84B cell-derived lung metastases [ Figure 8(b) ]. As we did not observed an elevation in AKT activation in DU145 FAM84B cells compared with DU145 EV cells in vitro, these alterations were specific in metastasis, and likely result of the process of tumor growth in vivo. Collectively, these observations indicate a potential mechanism by which FAM84B facilitates PC growth in the lung.
FAM84B activates a network in vivo
The role of FAM84B overexpression in promoting PC tumorigenesis is in line with the low level of FAM84B protein expression in prostate among other human tissues ( Figure S5 ). To investigate the mechanisms whereby FAM84B enhances xenograft growth, we have profiled the transcriptome of tumors produced by DU145 EV cells (n = 2) or DU145 FAM84B cells (n = 2). The probability of DEGs for the setting of two tumor types (groups) and two tumors per group were determined by the Poisson distribution statistical module; the analyses were performed by BGI (see Methods for details) using an algorithm developed by BGI. In reference to the significant elevation of FAM84B mRNA in DU145 FAM84B cell-produced xenografts compared with DU145 EV cell-derived tumors [ Figure 6 (b)], DEGs were defined using the probability (0.319383) which selects FAM84B as one of the DEGs, that is DEGs were selected by their probability ⩾0.319383 (Table S1 ); a total of 4976 DEGs were found (Table S1 ).
We then analyzed pathways that were enriched by these 4976 DEGs. Using the Reactome package in R, 51 pathways were found to be enriched (Table S2 ). Enrichment map revealed that these pathways were clustered in four major processes: the Golgi-to-ER process, cell cycle checkpoint, mitochondrial events, and protein translation ( Figure 9 ). In line with this enrichment map analysis, the top 12 enriched pathways were within these processes [ Figure 10(a, b) ]. As expected, the alterations among the top five pathways were largely overlapped; these five pathways are connected to the enriched pathway of cellular response to stress ( Figure S6 ). Additionally, the directionality (upregulation and downregulation) of the component DEGs in these pathways were also illustrated ( Figure S6 ).
We further analyzed pathway enrichment using Gene Set Enrichment Analysis (GSEA). Consistent with the above analyses, significant downregulation of the gene set regulating cellular responses to stress in DU145 FAM84B cell-generated xenografts was observed ( Figure 11 ; R-HSA-2262752). Downregulation of gene sets functioning in G2/M checkpoints and cell cycle checkpoints were also detected ( Figure 11 ; R-HSA-69481 and R-HSA-69620). These reductions would be expected to facilitate xenograft growth, which is supported by the data presented in Figure 6 . Reduction in the citric acid cycle (CTA) and respiratory electron transport ( Figure 11 ; R-HSA-1428517) is supported with the enriched pathways regulating mitochondrial events ( Figure 9 ). In DU145 FAM84B cell-derived tumors, the ubiquitination-involved processes were altered ( Figure  11 ; R-HSA-5688426). Tumorigenesis and tumor progression are associated with alterations in DNA methylation and global hypomethylation 58 ; of note, xenografts produced by DU145 FAM84B cells exhibited a reduction in the gene set regulating DNA methylation in comparison with tumors derived from DU145 EV cells (Figure 11 ; R-HSA-5334118).
Building a multigene signature predicting PC recurrence
The pathway enrichment analyses above suggests an association of the 4976 DEGs with PC progression; among which BCR was found to significantly increase the risk of PC metastasis. 10 We thus analyzed a potential association of the 4976 DEGs with BCR. TCGA provisional genomic dataset of PC within the cBioPortal database contains 499 tissue samples with follow-up data and mRNA profiles from RNA sequencing. From this cohort, 490 PC tissues/patients were used for model building. Following our previously established conditions, 59-61 the downregulated DEGs (n = 2471) were analyzed at 1.5 × SD (standard deviation), −1.5 × SD below a reference population mean, and the upregulated DEGs (n = 2505) were evaluated at 2 × SD above a reference population mean [ Figure 12 (a)]. All tumors (n = 490) were assigned a binary code of '1' if downregulated DEGs were expressed <−1.5 × SD, or upregulated DEGs were expressed >2 × SD; otherwise tumors were assigned '0'. This reorganized population was then used to analyze the impact of DEGs (n = 4976) on PC recurrence with elastic-net regression within the R glmnet package with 10-fold cross validation. To enhance the selection of highly correlated covariate as a group, the mixing parameter α was set at 0.2, 0.5 and 0.8; for each mixing parameter, six independent selections were performed. The core DEGs present in all selections plus unique DEGs with a total of 51 genes were initially selected. We then used a different approach to reanalyze these 51 DEGs; cutoff points to separate PC recurrence were estimated using Maximally Selected Rank Statistics in R. Each tumor was then given a Figure 9 . Enrichment mapping of the pathways enriched in DU145 FAM84B xenografts. Pathway enrichment analysis was performed using Reactome in R (see Table S2 for details of enriched pathways); each circular symbol represents individual pathways. The connections among these pathways are shown. The presentation was generated using Reactome in R.
binary code '0' or '1' accordingly; the individual component gene was analyzed for an association with PC recurrence by univariate Cox proportional hazards (PH) regression analysis; the PH assumption were confirmed. All component genes (n = 27) with a significant association with PC recurrence were selected to build SigFAM (Table 1) .
To analyze SigFAM's potential in stratification of the risk of PC recurrence, SigFAM scores were calculated for individual tumors using the (Table S1) were examined for pathway enrichment with the Reacome package in R. The top 12 pathways are included for the number of genes (a) and the gene ratio involved (b). The outline to build a multigene panel. TCGA provisional PC dataset (cBioPortal) was assigned according to the expression of downregulated DEGs and upregulated DEGs at the indicated levels; −1.5 × SD and 2 × SD indicate expression below and above a reference population mean. The reorganized cohort was subsequently examined for impact of these DEGs on PC recurrence (DFS) using the elastic-net regression (R glmnet package); the 27-gene SigFAM was the result. (b) PCs (n = 490) of the TCGA cohort were scored for SigFAM, which was analyzed for discrimination of PC recurrence using tROC. tAUC together with the status of PC recurrence are graphed.
(c) SigFAM scores were estimated for a cutoff point to separate PC recurrence (see Figure S7 ), followed by analyzing its stratification of the high-risk group of PC recurrence. Numbers of patient at risk during the indicated follow-up period are given. (d-f) SigFAM was analyzed to separate PCs at risk of recurrence using its Q1 score (d), Median score (e), and Q3 score (f). Kaplan-Meier curve and log-rank test were performed with the Survival package in R.
AUC, area under the curve; DEG, differentially expressed gene; DFS, disease-free survival; MDF, months disease free; MMDF, median months disease free; NA, MMDF was not reached; PC, prostate cancer; SD, standard deviation; tAUC, AUC at the indicated time; TCGA, The Cancer Genome Atlas; tROC, time-dependent receiver operating characteristic. Figure 12 (c)]. However, the CCP was analyzed using SD-based alterations here, while it was a real-time PCR-based assay in the clinic. It is likely that its predictive potential is underestimated in our system. Nonetheless, this analysis indicates that SigFAM should display comparable effectiveness as CCP in stratification of PC recurrence.
Characterization and validation of SigFAM
We noticed a subgroup of the SigFAM component genes that separate the high-risk population of PC recurrence with p value ⩽8.9e −5 , including UFM1, CHEK2, CRIP2, RELT, TICRR, VWA5B2, FOXM1, TRIM65, ASF1B, and RAD54L (Table 1) . These genes were grouped into a sub-signature SigFAM1; its scores discriminate PC recurrence with tAUC 0.816 at 11.6 months, 0.776 at 22. . While SigFAM classifies the risk of PC recurrence with sensitivity 63.7%, specificity 79.9%, and PPV 42%, SigFAM1 stratifies PC recurrence risk at sensitivity 33%, specificity 95%, and PPV 60%. It thus may be optimal to combine SigFAM1 and SigFAM in the evaluation of early recurrence to achieve sensitivity, specificity, and PPV at 63.7%, 95%, and 60% respectively.
As SigFAM1 forms the core of SigFAM, we validated its biomarker value of PC recurrence using an independent cohort. The Memorial Sloan Kettering Cancer Center (MSKCC) 64 PC dataset within cBioPortal has 140 patients/ primary tumors with a follow-up period up to 140 months and were profiled for mRNA expression using DNA microarray (cBioPortal). Following our system as described above, we analyzed the component genes of SigFAM1 for associations with PC recurrence using their cutoff points. Univariate Cox analysis revealed that they all individually predicted PC recurrence (Table 2 ). Similar to the situation observed in the TCGA provisional cohort [ Figure 13(b) ], SigFAM1 displays specific effectiveness in the stratification of early recurrence in the MSKCC cohort [ Figure 13(c) ].
We also analyzed the biomarker value of SigFAM using the MSKCC cohort. Following the same system as described above, we showed that 23 out Figure S8 (a)]; its cutoff point powerfully stratifies PCs at risk of recurrence [ Figure  S8 (b)]. Similar to the performance of SigFAM in the TCGA cohort, its Q1 has an application to separate out PCs that are least likely to relapse [ Figure S8 (c)]. Considering these results were obtained using an independent population which employed a different approach (microarray) to determine tumor transcriptomes, it serves to validate SigFAM as an effective signature in the prediction of PC recurrence.
SigFAM is a novel set of molecular biomarkers of PC recurrence
To further appreciate the biomarker potential of SigFAM, we performed a preliminary analysis of the 23 component genes, which predict PC recurrence in both the TCGA and MSKCC cohorts, for their relevance in PC and tumorigenesis in general (Table 3) . Among these 23 genes, 16 have not been reported in PC and 6 genes (RELT, CLBA1, KIF9, CCDC137, VWA5B2, and SCML2) are unknown to function in tumorigenesis (Table 3) . Among the rest 10 potential PC genes, UFM1 is downregulated in reference to FAM84B overexpression and is able to activate CDK5-associated tumor suppression 65 ; both FAAP24 and TICRR function in DNA damage response, which is highly relevant in tumorigenesis 66, 67 ; while CRIP2 is upregulated in FAM84B xenografts, and may act to repress tumorigenesis 68 ; RAB32, TRIM65, ADCY7, and ITGA11 promote tumorigenesis in gastric and endometrial adenocarcinoma, 69 bladder cancer, 70 acute myeloid leukemia, 71 and lung cancer 72 ; LRWD1 plays a role in cell cycle progression 73 ; and TIAM2 enhances Rac1 signaling 74 (Table 3 ).
There are seven other component genes that contribute to PC, including PPA2, 75 CHEK2, 76 FOXM1, 77 SYK, 78 ASF1B, 79 BGN, 80 and RAD54L 81 (Table 3) . ASF1B enhances PC via activation of the PI3K/AKT pathway. 79 Upregulation of BGN is associated with PTEN deletion and poor prognosis in PC. 80 RAD54L is associated with CRPC development. 81 Collectively, the existing knowledge supports that SigFAM is a novel and robust signature of PC recurrence. (Table 4) . Furthermore, 13 of the 27 SigFAM component genes, including 8 of 10 SigFAM1 component genes, remain independent risk factors in predicting PC recurrence after adjusting for age at diagnosis, GSs, surgical margin, and T tumor stage (Table 5 ). In view of their single gene status, their potentials to independently predict PC recurrence after adjusting for the aforementioned clinical factors further strengthened their potential in the evaluation of PC recurrence; these properties contribute to the robust nature of SigFAM in stratification of PCs at risk of recurrence.
SigFAM independently predicts PC recurrence
Discussion
Although FAM84B resides in the most frequently amplified chromosome locus 8q24, 31, 82 research on the protein's potential role in human cancers has been very limited, even considering the recent evidence for its association with esophageal squamous cell carcinoma 43, 44 and PC. 45 We report here a thorough research effort supporting FAM84B's role in PC and the complex network through which FAM84B contributes to PC.
The properties of FAM84B in promoting PC progression are supported by its overexpression enhancing DU145 cell-derived oncogenic processes in vitro and in vivo (xenograft tumors and lung metastasis). Importantly, we described the first structural analysis that revealed a relationship of FAM84B with the HRASLS family. FAM84B shares a LRAT motif with the family (Figure 3) , and conserved two histidine (His) residues among the catalytic triad ( Figure 2) . FAM84B is thus a remote HRASLS family member. All five members of the HRASLS family in humans have enzymatic activities of phospholipase A 1/2 and O-acyltrasferase 46 ; HRASLS1-5 are able to suppress H-Ras-derived oncogenesis and are downregulated in human cancers 46 ; evidence also supports a contribution of their enzymatic activities in tumor suppression. 46 Since the catalytic residue Cys is not conserved (Figure 2 ), FAM84B is unlikely to have either enzymatic activities, which implies that FAM84B facilitates journals.sagepub.com/home/tam 21 Ras signaling. This possibility is intriguing. Myc is well demonstrated to collaborate with Ras in tumorigenesis; [23] [24] [25] FAM84B is likely co-amplified with Myc owing to both genes bordering the 8q24.1 gene desert. 31, 42, [82] [83] [84] It is thus tempting to propose that the co-amplification facilitates MycRas collaboration in part via FAM84B upregulation. Additionally, it is possible that FAM84B may reduce the actions of HRASLS1-5, thereby facilitating Ras signaling. As FAM84B may undergo intramolecular interaction in vivo ( Figure 5 ), whether this is involved in FAM84B's action in PC remains to be explored. Further research is required to investigate the above concepts.
The above concepts seem to suggest indirect impacts of FAM84B on PC progression. This possibility is supported by the lack of effects in DU145 cell proliferation in vitro following FAM84B overexpression [ Figure 1(b) ] and the modest enhancement of tumor growth in the s.c. space and lung by ectopic FAM84B expression. Similar situation was also observed in BMI1; ectopic expression of BMI1 in MCF7 cells did not promote xenograft growth without other oncogenic manipulations. 48 BMI1 is a well demonstrated oncogene that collaborates with c-Myc and other oncogenes. [85] [86] [87] In this regard, to better understand FAM84B-facilitated oncogenesis, it is important to have knowledge on the potential mechanisms regulating FAM84B's actions.
While the mechanisms underlying FAM84B-facilitated prostate tumorigenesis are yet to be pinpointed, our research suggests that these mechanisms, although not limited to, regulate Golgi-to-ER processes, cell cycle checkpoints, mitochondria events, and protein metabolism ( Figure 9 ). Among the Golgi-to-ER processes, the top pathways affected were those that regulate the Golgi-to-ER retrograde transport (Figure 10 ), which functions in tumorigenesis, including the epidermal growth factor receptor and Wnt signaling. 88, 89 One of the interesting mitochondrial events affected is the respiratory electron transport and ATP synthesis ( Figure  10 ), which is in line with the downregulation of the gene set of R-HAS-1428517 regulating the tricarboxylic acid cycle and respiratory electron transport ( Figure 11 ). This suggests that FAM84B facilitates the Warburg metabolism or aerobic glycolysis in PC, the key pattern of cancer metabolism. 90 While the mechanisms for FAM84B to alter these processes and their contributions to FAM84B-mediated prostate tumorigenesis are not clear, it is likely that the network affected by FAM84B is relevant to PC. This interpretation is supported by the derivation of the multigene signature SigFAM, and its sub-signature SigFAM1. Both signatures are novel and robustly stratify the highrisk population of PC recurrence in two independent cohorts. SigFAM can be explored for its Finally, it is likely that the results obtained in this research are not limited to PC. It will be interesting to investigate the involvement of FAM84B in cancers produced from those tissues expressing the FAM84B protein at the medium to high levels, like endometrium, cervix, breast, kidney, liver, lung, and others ( Figure S5 ).
We have examined FAM84B-derived oncogenic effects with multiple systems including functional studies (in vitro and in vivo), mechanistic approaches (RNA sequencing with duplicates), and clinical significance investigations (modeling FAM84B-associated DEGs). However, this study has several limitations. (1) Horizontally expanding the knowledge obtained from this study in other PC cell lines, particularly androgen-dependent PC cells like LNCaP cells will strengthen this study, if similar effects are demonstrated. However, we like to emphasize that negative results will not weaken this investigation. (2) The association between the identified network or DEGs and FAM84B functions warrant further investigation; this research likely requires a major effort. (3) The multigene signature built here certainly requires further tests; how this signature is related with FAM84B functions should be investigated in future studies.
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